Please pardon my charting. I find it is best to combine TA and some DD for the best trades lately. Definitely a solid level of resistance and higher lows in the weeks leading up.
Notes regarding the drug in question, Rilonacept, which addresses recurrent pericarditis.
"In RHAPSODY, the primary efficacy endpoint of time-to-first adjudicated pericarditis...
Announced that six COVID-19 patients treated with mavrilimumab in Italy all responded to treatment, and 3 patients were discharged within 5 days.
A follow-on controlled study in Italy is planned. Shares closed the week up 43% to $17.91.
Breaking through the recent top will be a strong indicator for further upside movement.
Hovering aorund the...